0
0
Airbnb — Shares of the holiday rental firm dropped 8.13%, a day after popping 13.35% on a stronger-than-expected fourth-quarter earnings report. Some Wall Street analysts remained cautious on the inventory, citing dangers together with competitors and slower-than-expected shopper adoption of different lodging.
Albemarle — The specialty chemical compounds firm sank 9.67%, a day after gaining almost 5%. Albemarle reported an adjusted earnings-per-share beat after the bell Wednesday, in addition to income that was in-line with expectations, per StreetAccount.
Bio-Rad Laboratories — Shares rose 5.99% after the corporate reported fourth-quarter internet revenue of $827.7 million, after reporting a loss in the identical interval a 12 months prior. The firm’s non-operating margin additionally elevated to 17.4% from 15.7% within the year-earlier interval. Still, earnings and income missed Wall Street estimates.
Airbnb — Shares of the holiday rental firm dropped 8.13%, a day after popping 13.35% on a stronger-than-expected fourth-quarter earnings report. Some Wall Street analysts remained cautious on the inventory, citing dangers together with competitors and slower-than-expected shopper adoption of different lodging.
Albemarle — The specialty chemical compounds firm sank 9.67%, a day after gaining almost 5%. Albemarle reported an adjusted earnings-per-share beat after the bell Wednesday, in addition to income that was in-line with expectations, per StreetAccount.
Bio-Rad Laboratories — Shares rose 5.99% after the corporate reported fourth-quarter internet revenue of $827.7 million, after reporting a loss in the identical interval a 12 months prior. The firm’s non-operating margin additionally elevated to 17.4% from 15.7% within the year-earlier interval. Still, earnings and income missed Wall Street estimates.
Zebra Technologies — Shares dropped 3.26% after the corporate predicted gross sales would drop barely for the complete 12 months. CEO Anders Gustafsson mentioned he’s taking a “cautious method” to the outlook based mostly on an unsure macro setting. Zebra’s fourth-quarter earnings and income, nevertheless, topped Wall Street estimates.
AutoNation — The automotive dealership’s inventory gained 11.35% after the corporate beat fourth-quarter revenue and gross sales expectations. AutoNation reported adjusted earnings of $6.37 per share, versus Refinitiv’s estimate of $5.83. Its income of $6.7 billion topped the $6.52 billion anticipated.
DraftKings — Shares jumped 15.33% after DraftKings reported fourth-quarter outcomes that topped expectations. The sports activities betting firm reported a lack of 53 cents per share on income of $855 million. Analysts polled by Refinitiv anticipated a lack of 59 cents per share on income of $800 million.
Moderna — The biotech inventory dropped 3.31% after its influenza vaccine candidate posted combined leads to medical trials.
Redfin — Shares fell 6.55% even after Redfin reported better-than-expected fourth-quarter outcomes. The actual property firm reported a 57 cent per share loss on $480 million of income. Analysts have been forecasting a lack of $1.08 per share on $445 million of income, in keeping with consensus estimates from Refinitiv. Still, income declined 12 months over 12 months.
Roku — Shares of the streaming machine firm erased early positive factors amid the broader sell-off on Wall Street. The inventory first traded greater after Bank of America double upgraded the inventory to purchase from underperform because the Wall Street agency mentioned Roku is on path to income and margin enchancment. It ended down 1.4%.
DoorDash — Shares of the meals supply firm fell 7.59% after DoorDash reported a combined fourth quarter. DoorDash reported $1.82 billion in income for the quarter, above the $1.77 billion anticipated in keeping with Refinitiv, and delivered upbeat steerage. However, the corporate’s lack of $1.65 per share was greater than twice as vast as analysts anticipated.
Biogen — Shares of the biopharmaceutical firm rose 2.52% after Japanese drugmaker Eisai mentioned it expects the Food and Drug Administration to totally approve its Alzheimer’s remedy Leqembi this summer time. Eisai developed the drug with Biogen.
— Shares dropped 3.26% after the corporate predicted gross sales would drop barely for the complete 12 months. CEO Anders Gustafsson mentioned he’s taking a “cautious method” to the outlook based mostly on an unsure macro setting. Zebra’s fourth-quarter earnings and income, nevertheless, topped Wall Street estimates.
AutoNation — The automotive dealership’s inventory gained 11.35% after the corporate beat fourth-quarter revenue and gross sales expectations. AutoNation reported adjusted earnings of $6.37 per share, versus Refinitiv’s estimate of $5.83. Its income of $6.7 billion topped the $6.52 billion anticipated.
DraftKings — Shares jumped 15.33% after DraftKings reported fourth-quarter outcomes that topped expectations. The sports activities betting firm reported a lack of 53 cents per share on income of $855 million. Analysts polled by Refinitiv anticipated a lack of 59 cents per share on income of $800 million.
Moderna — The biotech inventory dropped 3.31% after its influenza vaccine candidate posted combined leads to medical trials.
Redfin — Shares fell 6.55% even after Redfin reported better-than-expected fourth-quarter outcomes. The actual property firm reported a 57 cent per share loss on $480 million of income. Analysts have been forecasting a lack of $1.08 per share on $445 million of income, in keeping with consensus estimates from Refinitiv. Still, income declined 12 months over 12 months.
Roku — Shares of the streaming machine firm erased early positive factors amid the broader sell-off on Wall Street. The inventory first traded greater after Bank of America double upgraded the inventory to purchase from underperform because the Wall Street agency mentioned Roku is on path to income and margin enchancment. It ended down 1.4%.
DoorDash — Shares of the meals supply firm fell 7.59% after DoorDash reported a combined fourth quarter. DoorDash reported $1.82 billion in income for the quarter, above the $1.77 billion anticipated in keeping with Refinitiv, and delivered upbeat steerage. However, the corporate’s lack of $1.65 per share was greater than twice as vast as analysts anticipated.
Biogen — Shares of the biopharmaceutical firm rose 2.52% after Japanese drugmaker Eisai mentioned it expects the Food and Drug Administration to totally approve its Alzheimer’s remedy Leqembi this summer time. Eisai developed the drug with Biogen.
